

# Lavinia Arend

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9362401/publications.pdf>

Version: 2024-02-01

28  
papers

467  
citations

759233

12  
h-index

713466

21  
g-index

30  
all docs

30  
docs citations

30  
times ranked

638  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant <i>Pseudomonas aeruginosa</i> and KPC-producing Enterobacterales. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115568.  | 1.8 | 8         |
| 2  | Resolving taxonomic confusion: establishing the genus <i>Phytobacter</i> on the list of clinically relevant Enterobacteriaceae. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 547-558.   | 2.9 | 3         |
| 3  | A carbapenem-resistant <i>Acinetobacter baumannii</i> outbreak associated with a polymyxin shortage during the COVID pandemic: an <i>in vitro</i> and biofilm analysis of synergy between meropenem, gentamicin and sulbactam. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , . | 3.0 | 4         |
| 4  | Distribution of genes encoding 16S rRNA methyltransferase in plazomicin-nonsusceptible carbapenemase-producing Enterobacterales in Brazil. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115239.  | 1.8 | 7         |
| 5  | The activity of ceftazidime/avibactam against carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>Infectious Diseases</i> , 2021, 53, 386-389.  | 2.8 | 3         |
| 6  | Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0153621.  | 3.9 | 4         |
| 7  | Resistance of clinical and environmental <i>Acinetobacter baumannii</i> against quaternary ammonium. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-3.  | 1.8 | 1         |
| 8  | Antagonistic effect between tigecycline and meropenem: from bed to bench to bed. <i>Infection</i> , 2020, 48, 141-142.  | 4.7 | 0         |
| 9  | Elution methods to evaluate colistin susceptibility of Gram-negative rods. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114910.  | 1.8 | 13        |
| 10 | Low level of polymyxin resistance among nonclonal mcr-1 positive <i>Escherichia coli</i> from human sources in Brazil. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 140-142.   | 1.8 | 16        |
| 11 | Validation of multiplex PCR for the diagnosis of acute bacterial meningitis in culture negative cerebrospinal fluid. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 224-231.  | 0.8 | 10        |
| 12 | Molecular investigation of isolates from a multistate polymicrobial outbreak associated with contaminated total parenteral nutrition in Brazil. <i>BMC Infectious Diseases</i> , 2018, 18, 397.   | 2.9 | 15        |
| 13 | Molecular epidemiology of SPM-1-producing <i>Pseudomonas aeruginosa</i> by rep-PCR in hospitals in Parana, Brazil. <i>Infection, Genetics and Evolution</i> , 2017, 49, 130-133.  | 2.3 | 14        |
| 14 | Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae. <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 1-6.   | 0.6 | 31        |
| 15 | Colistin-resistant Enterobacteriaceae bacteraemia: real-life challenges and options. <i>Clinical Microbiology and Infection</i> , 2016, 22, e9-e10.   | 6.0 | 12        |
| 16 | Molecular epidemiology of <i>Klebsiella pneumoniae</i> carbapenemase-producing Enterobacteriaceae in different facilities in Southern Brazil. <i>American Journal of Infection Control</i> , 2015, 43, 137-140.   | 2.3 | 14        |
| 17 | Phenotypic and molecular characterization of 942 carbapenem-resistant Enterobacteriaceae (CRE) in southern Brazil. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 316-318.  | 1.7 | 5         |
| 18 | KPC-producing <i>Enterobacter aerogenes</i> infection. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 324-327.   | 0.6 | 20        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Activity of Antimicrobial Combinations against KPC-2-Producing <i>Klebsiella pneumoniae</i> in a Rat Model and Time-Kill Assay. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4301-4304.  | 3.2 | 23        |
| 20 | First Report of NDM-1-Producing <i>Acinetobacter baumannii</i> Sequence Type 25 in Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7592-7594.   | 3.2 | 54        |
| 21 | Efficacy of tigecycline, polymyxin, gentamicin, meropenem and associations in experimental <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>Klebsiella pneumoniae</i> non-lethal sepsis. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 574-575. | 0.6 | 7         |
| 22 | Molecular epidemiology characterization of OXA-23 carbapenemase-producing <i>Acinetobacter baumannii</i> isolated from 8 Brazilian hospitals using repetitive sequence-based PCR. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 337-340.         | 1.8 | 36        |
| 23 | Treatment and outcome of nine cases of KPC-producing <i>Klebsiella pneumoniae</i> meningitis. <i>Journal of Infection</i> , 2013, 67, 161-164.   | 3.3 | 12        |
| 24 | Risk factors for KPC-producing <i>Klebsiella pneumoniae</i> bacteremia. <i>Brazilian Journal of Infectious Diseases</i> , 2012, 16, 416-419.   | 0.6 | 49        |
| 25 | Valida o do teste de inibi o pelo  cido aminofenilbor nico para triagem de <i>Klebsiella pneumoniae</i> carbapenemases (KPC). <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2012, 48, 427-433.   | 0.3 | 0         |
| 26 | Surveillance programme for multidrug-resistant bacteria in healthcare-associated infections: an urban perspective in South Brazil. <i>Journal of Hospital Infection</i> , 2012, 80, 351-353.   | 2.9 | 27        |
| 27 | Virulence characteristics and antimicrobial susceptibility of uropathogenic <i>Escherichia coli</i> strains. <i>Genetics and Molecular Research</i> , 2011, 10, 4114-4125.   | 0.2 | 68        |
| 28 | Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant <i>Acinetobacter</i> ?. <i>Journal of Infection</i> , 2011, 62, 246-249.   | 3.3 | 11        |